<DOC>
	<DOCNO>NCT00600938</DOCNO>
	<brief_summary>This clinical research study patient iron overload heart due chronic blood transfusion . The study 2 treatment group compare safety efficacy chelation therapy medicine call deferasirox ( ICL670 ) another medicine call deferoxamine ( DFO ) . The study aim find two medicine best treat iron overload heart . Patients treat 12 month ( core study phase ) . Patients complete core study phase offer continue study treatment 12 month extension phase . During core extension , effect treatment iron overload heart liver evaluate use specific magnetic resonance imaging ( MRI ) assessment .</brief_summary>
	<brief_title>Evaluating Use Deferasirox Compared Deferoxamine Treating Cardiac Iron Overload</brief_title>
	<detailed_description />
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>Hemosiderosis</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<mesh_term>Deferoxamine</mesh_term>
	<criteria>Inclusion criterion : Male female patient , age 10 year , βthalassemia major DBA sideroblastic anemia chronic transfusion therapy , give write consent participate study . Patients cardiac iron measure myocardial T2* value ≥ 6ms ≥ 20 m . Patients lifetime history least 50 unit red cell transfusion , must receive least ≥10 units/yr red blood cell transfusion . Patients leave ventricular ejection fraction ( LVEF ) ≥ 56 % determine cardiovascular magnetic resonance ( CMR ) . Patients liver iron content ( LIC ) value ≥ 3 mg Fe / g dw , determine liver MRI . Exclusion criterion : Patients clinical symptom cardiac dysfunction . Patients unable undergo study assessment include MRI Patients participate another clinical trial receive investigational drug . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>iron overload</keyword>
	<keyword>cardiac iron</keyword>
	<keyword>haemosiderosis</keyword>
	<keyword>myocardial T2*</keyword>
	<keyword>leave ventricular ejection fraction</keyword>
	<keyword>LVEF</keyword>
	<keyword>cardiac dysfunction</keyword>
	<keyword>thalassaemia</keyword>
	<keyword>Diamond Blackfan anemia</keyword>
	<keyword>DBA</keyword>
	<keyword>sideroblastic anemia</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>MDS ( low INT-1 risk per IPSS MDS )</keyword>
	<keyword>liver MRI</keyword>
	<keyword>deferasirox</keyword>
	<keyword>deferoxamine</keyword>
	<keyword>ICL670</keyword>
	<keyword>DFO</keyword>
	<keyword>cardiovascular magnetic resonance imaging</keyword>
</DOC>